NICE questions cost-effectiveness for Adtralza, Rinvoq and Cibinqo
The National Institute for Health and Care Excellence (NICE) does not recommend the agents for the treatment of atopic dermatitis.
By
The National Institute for Health and Care Excellence (NICE) does not recommend the agents for the treatment of atopic dermatitis.
ByGlobalData has identified drug candidates for osteoarthritis that could shift the competitive landscape and treatment paradigm.
BySanofi will make more than $6bn in development, regulatory, and commercial milestone payments to IGM.
Imbalance in the vaginal microbiome has been linked to a range of conditions, from UTIs to preterm birth.
ByPfizer will gain access to Arena’s portfolio of various treatment candidates for gastroenterology, dermatology and cardiology.
Pfizer’s Staquis and other PDE4 therapies for atopic dermatitis may soon be outpaced by treatments with other methods of action.
ByThe approval is based on data from the clinical development programme of Saphnelo, including the TULIP and MUSE trials.
The approval is based on findings from the Phase III BLISS-LN clinical trial of belimumab in adults with active LN.
Thank you for subscribing to Pharmaceutical Technology